PE
OCUL icon

Point72 Europe’s Ocular Therapeutix OCUL Stock Holding History

Point72 Europe’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$68.1K Buy
+5,825
New +$69.7K ﹤0.01% 327

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Europe's OCUL Position: Q3 2025 in Review

Point72 Europe opened a new position in Ocular Therapeutix (OCUL) in Q3 2025: 5,825 shares worth $68.1K. The stake represents ﹤0.01% of the portfolio and ranks #327 among its holdings.

216 funds tracked by Wall St. Rank hold OCUL as of Q3 2025.

  • Point72 Europe held 5,825 shares of Ocular Therapeutix worth $68.1K as of Q3 2025.
  • Ocular Therapeutix was a new Point72 Europe position in Q3 2025.
  • Ocular Therapeutix made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #327 holding.
  • 216 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.